Submission & ApprovalLast reviewed April 2026

Breakthrough Therapy Designation(BTD)

An FDA designation for drugs showing substantial improvement over existing treatments for serious conditions.

Usage Examples

The CAR-T therapy received Breakthrough Therapy Designation.
BTD enabled extensive FDA interaction during development.
The breakthrough designation was based on Phase 2 response rates.

What is BTD?

Breakthrough Therapy Designation (BTD) is an FDA program to expedite development and review of drugs that may demonstrate substantial improvement over available therapies for serious or life-threatening conditions.

To qualify, preliminary clinical evidence must show the drug may demonstrate substantial improvement on clinically significant endpoints compared to existing treatments. Benefits of BTD include intensive FDA guidance on efficient development, organizational commitment involving senior managers, and rolling review of the application.

BTD is distinct from other expedited programs (Fast Track, Accelerated Approval, Priority Review) though drugs may qualify for multiple designations. BTD does not change approval standards but aims to get promising drugs to patients faster.

Regulatory Context

This term appears most often in submission & approval workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside FDASIA SECTION 902.

FDAICHEMA

When This Matters

The CAR-T therapy received Breakthrough Therapy Designation.
BTD enabled extensive FDA interaction during development.
The breakthrough designation was based on Phase 2 response rates.

Common Mistakes

Treating submission readiness as a formatting-only check without lifecycle validation.
Using outdated guidance references across modules and summaries.
Missing cross-functional review between RA, CMC, and quality before submission.

Related Regulations

FDASIA SECTION 902

How to Request FDA Breakthrough Therapy Designation

Submit a request for Breakthrough Therapy Designation to gain expedited development and review benefits for a serious condition drug.

1
Confirm eligibility
Verify: (1) drug treats a serious condition, (2) preliminary clinical evidence exists showing substantial improvement over available therapy on a clinically significant endpoint. Anecdotal experience is insufficient; preliminary clinical data is required.
2
Determine optimal timing
FDA recommends requesting no later than end-of-Phase-2. Earlier requests (with sufficient clinical evidence) are possible. Late requests during Phase 3 miss development benefits. Align timing with available clinical data and strategic development milestones.
3
Prepare the request document
Concise request typically under 50 pages covering: drug description, serious-condition justification, available therapy landscape, preliminary clinical evidence with analysis, clinical significance argument, and proposed development plan.
4
Submit via IND
File the Breakthrough Therapy Designation request as an IND amendment. FDA has 60 days to respond. No user fee applies.
5
Respond to FDA questions
FDA may request additional clinical evidence or analysis during the 60-day review. Prompt responses protect the review timeline. Denial can be appealed or re-requested with stronger evidence.
6
Leverage designation benefits
If granted: intensive FDA guidance (Type B meetings, rolling reviews), organizational commitment from senior FDA officials, eligibility for priority review and accelerated approval. Use senior FDA engagement to de-risk late-stage development.

Frequently Asked Questions

Benefits include intensive FDA guidance, organizational commitment from senior FDA managers, potential rolling review, and typically expedited development and review timelines.

BTD requires preliminary clinical evidence of substantial improvement, while Fast Track requires the drug to address an unmet need. BTD provides more intensive engagement including senior manager involvement.

No, BTD facilitates development but doesn't change approval standards or guarantee approval. However, BTD drugs often also receive Priority Review, which does expedite the review timeline.